Cargando…
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
BACKGROUND: Where health economic studies are frequently performed using modelling, with input from randomized controlled trials and best guesses, we used real-life data to analyse the cost-effectiveness and cost-utility of a treatment strategy aiming to the target of remission compared to usual car...
Autores principales: | Vermeer, Marloes, Kievit, Wietske, Kuper, Hillechiena H, Braakman-Jansen, Louise MA, Bernelot Moens, Hein J, Zijlstra, Theo R, den Broeder, Alfons A, van Riel, Piet LCM, Fransen, Jaap, van de Laar, Mart AFJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884120/ https://www.ncbi.nlm.nih.gov/pubmed/24330489 http://dx.doi.org/10.1186/1471-2474-14-350 |
Ejemplares similares
-
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
por: Vermeer, Marloes, et al.
Publicado: (2012) -
Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010) -
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015) -
Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis
por: Hendrikx, Jos, et al.
Publicado: (2016) -
How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis
por: Siemons, Liseth, et al.
Publicado: (2014)